KR980000447A - 미르타자핀과 하나 이상의 선택적인 세로토닌 재이용 저해제로 이루어진 약학 조성물 - Google Patents

미르타자핀과 하나 이상의 선택적인 세로토닌 재이용 저해제로 이루어진 약학 조성물 Download PDF

Info

Publication number
KR980000447A
KR980000447A KR1019970025307A KR19970025307A KR980000447A KR 980000447 A KR980000447 A KR 980000447A KR 1019970025307 A KR1019970025307 A KR 1019970025307A KR 19970025307 A KR19970025307 A KR 19970025307A KR 980000447 A KR980000447 A KR 980000447A
Authority
KR
South Korea
Prior art keywords
mirtazapine
composition
ssris
depression
pharmaceutically acceptable
Prior art date
Application number
KR1019970025307A
Other languages
English (en)
Other versions
KR100481254B1 (ko
Inventor
요한네스 니콜슨 빅토르
Original Assignee
에프. 지. 엠. 헤르만스; 이. 에이치. 리링크
악조 노벨 엔. 브이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224094&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR980000447(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 에프. 지. 엠. 헤르만스; 이. 에이치. 리링크, 악조 노벨 엔. 브이 filed Critical 에프. 지. 엠. 헤르만스; 이. 에이치. 리링크
Publication of KR980000447A publication Critical patent/KR980000447A/ko
Application granted granted Critical
Publication of KR100481254B1 publication Critical patent/KR100481254B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 미르타자핀, 선택적인 세로토닌 재이용 저해제(SSRI) 그리고 약학적 허용 보조제를 포함하는 약학 조성물에 관한 것이다. 특히 SSRI는 플루옥세틴(fluoxetin), 플루복사민(fluvoxamine), 시타로프람(citalopram), 세리클라민(cericlamine) 페목세틴(femoxetin), 세르트랄린(sertraline), 파록세틴(paroxetin), 이폭세틴(ifoxetine) 시아노도티에핀(cyanodothiepin) 및 리톡세틴(litoxetine)으로부터 선택된다. 우울증 환자를 치료하기 위해 이용될 수 있는 상기 조성물은 미르타자핀 또는 SSRI만으로 환자를 치료하는 것보다 더 적은 부작용을 가진다.

Description

미르타자핀과 하나 이상의 선택적인 세로토닌 재이용 저해제로 이루어진 약학 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 미르타자핀 또는 그들의 약학적 허용염과 하나 또는 그 이상의 SSRI 또는 그들의 약학적 허용염을 포함하는 조성물.
  2. 제1항에 있어서, 상기 SSRI가 지멜딘, 플루옥세틴, 플루복사민, 시타로프람, 세리클라민, 페목세틴, 이폭세틴, 시아노도티에핀, 세르트랄린, 파록세틴, 및 리톡세틴으로부터 선택된 조성물.
  3. 제1항에 있어서, 미르타자핀과 플루옥세틴을 포함하는 조성물.
  4. 제1항 내지 제3항 중의 어느 한 항에 있어서, 우울증 치료 용도를 위한 조성물.
  5. 제1항 내지 제3항 중의 어느 한 항에 따른 조성물을, 그들을 위한 하나 또는 그 이상의 약학적 허용 담체와 결합하여 포함하는 약학 제제.
  6. 제1항 내지 제3항 중의 어느 한 항에 정의된 조성물 또는 제5항에 설명된 제제를 치료적으로 유효한 양으로 동물을 치료하는 것을 포함하는, 동물의 우울증 치료 방법.
  7. 최소의 부작용을 가지는 항우울증 활성을 가지는 약제 제조에서 미르타자핀과 하나 또는 그 이상의 SSRI의 용도.
  8. 우울증 치료를 위해 미르타자핀과 동시에 또는 순차적으로 투여하기 위한 약제 제조에서 하나 또는 그 이상의 SSRI의 용도.
  9. 우울증 치료를 위해 하나 또는 그 이상의 SSRI와 동시에 또는 순차적으로 투여하기 위한 약제 제조에서 미르타자핀의 용도.
  10. 하나 또는 그 이상의 투여 단위가 미르타자핀을 함유하고 하나 또는 그 이상의 다른 투여 단위가 SSRI, 바람직하게는 플루옥세틴을 함유하는, 분리된 투여 단위를 포함하는 패키지(package).
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970025307A 1996-06-19 1997-06-18 미르타자핀과하나이상의선택적인세로토닌재흡수저해제를포함하는약학조성물 KR100481254B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96201703.4 1996-06-19
EP96201703 1996-06-19

Publications (2)

Publication Number Publication Date
KR980000447A true KR980000447A (ko) 1998-03-30
KR100481254B1 KR100481254B1 (ko) 2005-09-12

Family

ID=8224094

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970025307A KR100481254B1 (ko) 1996-06-19 1997-06-18 미르타자핀과하나이상의선택적인세로토닌재흡수저해제를포함하는약학조성물

Country Status (25)

Country Link
US (1) US5977099A (ko)
JP (2) JP4925074B2 (ko)
KR (1) KR100481254B1 (ko)
CN (1) CN1132581C (ko)
AR (1) AR007609A1 (ko)
AT (1) ATE213159T1 (ko)
AU (1) AU727851B2 (ko)
BR (1) BR9703624A (ko)
CA (1) CA2208199C (ko)
CZ (1) CZ290691B6 (ko)
DE (1) DE69710390T2 (ko)
DK (1) DK0813873T3 (ko)
ES (1) ES2172744T3 (ko)
HK (1) HK1006081A1 (ko)
HU (1) HU225534B1 (ko)
ID (1) ID17051A (ko)
IL (1) IL121076A (ko)
NO (1) NO313177B1 (ko)
NZ (1) NZ328113A (ko)
PL (1) PL188520B1 (ko)
PT (1) PT813873E (ko)
RU (1) RU2181287C2 (ko)
SG (1) SG60073A1 (ko)
TR (1) TR199700522A3 (ko)
ZA (1) ZA975335B (ko)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
IL135825A0 (en) * 1997-11-14 2001-05-20 Akzo Nobel Nv Use of mirtazapine for treating sleep apneas
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
US6727283B2 (en) 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
US6575147B2 (en) * 1999-02-25 2003-06-10 Go-Tec Internal combustion system adapted for use of a dual fuel composition including acetylene
AU781221B2 (en) * 1999-04-19 2005-05-12 Teva Pharmaceutical Industries Ltd. Novel synthesis and crystallization of piperazine ring-containing compounds
US6545149B2 (en) 1999-04-19 2003-04-08 Teva Pharmaceutical Industries Ltd. Synthesis and crystallization of piperazine ring-containing compounds
US6759437B2 (en) * 1999-10-04 2004-07-06 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity including cysteine
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
IL150289A0 (en) * 2000-01-19 2002-12-01 Akzo Nobel Nv Drug combination for the treatment of depression and related disorders comprising mirtazapine
WO2002036113A1 (en) * 2000-11-01 2002-05-10 Respiratorius Ab Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4)
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
ATE380884T1 (de) * 2001-02-12 2007-12-15 Organon Nv Verwendung von mirtazapin zur verbesserung der behandlung von menschen mit starken depressionen, welche träger des gens für apolipoprotein e4 sind.
US20090311795A1 (en) * 2002-03-21 2009-12-17 Hinz Martin C Bilateral control of functions traditionally regulated by only serotonin or only dopamine
US20070293571A1 (en) * 2006-06-08 2007-12-20 Hinz Martin C Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes
CA2479218A1 (en) * 2002-03-21 2003-10-02 Martin C. Hinz Serotonin and catecholamine system segment optimization technology
ES2295677T3 (es) 2002-12-27 2008-04-16 Otsuka Pharmaceutical Co., Ltd. Derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del estado de animo.
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
WO2004075724A2 (en) * 2003-02-21 2004-09-10 Hinz Martin C Serotonin and catecholamine system segment optimization technology
TW200502222A (en) * 2003-04-02 2005-01-16 Novartis Ag Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
PT2316456T (pt) 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
US7838029B1 (en) 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
EP1667972B1 (en) 2003-09-10 2013-06-19 Brentwood Equities Ltd. Diastereomers of 4-aryloxy-3-hydroxypiperidines
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
TW200538100A (en) * 2004-04-21 2005-12-01 Akzo Nobel Nv Mirtazapine salts
WO2006023703A2 (en) * 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Method for treating sleep related breathing disorders
WO2006055854A2 (en) * 2004-11-17 2006-05-26 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtazapine treatment
CA2585317C (en) * 2004-11-19 2015-02-24 N.V. Organon Drug combination for the treatment of depression and related disorders comprising a selective serotonin reuptake inhibitor
WO2007067341A2 (en) 2005-11-22 2007-06-14 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20140088619A (ko) 2006-11-09 2014-07-10 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
ES2344440T3 (es) 2006-11-09 2010-08-26 Orexigen Therapeutics, Inc. Formulaciones farmaceuticas en capas que comprenden una capa intermedia de disolucion rapida.
WO2008157094A1 (en) * 2007-06-13 2008-12-24 Cypress Bioscience, Inc. Improving the tolerability of mirtazapine and a second active by using them in combination
CN101332193B (zh) * 2007-06-29 2012-12-12 杭州民生药业有限公司 一种马来酸氟伏沙明药物组合物的制备方法
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
JP5198660B2 (ja) 2009-06-09 2013-05-15 住友重機械工業株式会社 ハイブリッド式ショベル及びその制御方法
WO2011059207A2 (en) * 2009-11-13 2011-05-19 Green Cross Corporation Arylpiperazine-containing purine derivatives and uses thereof
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
CN102000334B (zh) * 2010-10-15 2012-02-22 北京大学 用于治疗抑郁症的复方制剂
RU2475235C2 (ru) * 2011-03-15 2013-02-20 Общество с ограниченной ответственностью "ЭР ЭНД ДИ ФАРМА" Фармацевтическая композиция для профилактики и лечения депрессивных состояний
AR085840A1 (es) * 2011-04-05 2013-10-30 Otsuka Pharma Co Ltd Medicamento que contiene un compuesto que es 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona
PE20150358A1 (es) 2012-06-06 2015-04-06 Orexigen Therapeutics Inc Metodos para el tratamiento del sobrepeso y de la obesidad

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189199C (nl) * 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
AU8770282A (en) * 1981-08-27 1983-03-03 Shaun R. Coughlin Composition for the treatment of atherosclerosis
US4940585A (en) * 1989-02-17 1990-07-10 Hapworth William E Method for the treatment of nicotine withdrawal syndrome
US5208261A (en) * 1989-12-06 1993-05-04 Akzo N.V. Stabilized solutions of psychotropic agents
ATE99943T1 (de) * 1989-12-06 1994-01-15 Akzo Nv Psychotropische wirkstoffe enthaltende stabilisierte loesungen.
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
IL123716A (en) * 1997-03-27 2001-03-19 Akzo Nobel Nv Therapeutic combinations of mirtazapine and an antipsychotic agent
CN1155410C (zh) * 1997-10-03 2004-06-30 卡里药品公司 治疗尼古丁成瘾的含有尼古丁受体拮抗剂和抗抑郁药或抗焦虑药的组合物

Also Published As

Publication number Publication date
HU225534B1 (en) 2007-02-28
IL121076A0 (en) 1997-11-20
DK0813873T3 (da) 2002-05-27
CA2208199C (en) 2006-10-24
HK1006081A1 (en) 1999-02-12
ES2172744T3 (es) 2002-10-01
NO972816D0 (no) 1997-06-18
IL121076A (en) 2000-10-31
CN1132581C (zh) 2003-12-31
BR9703624A (pt) 1998-09-01
AU2612997A (en) 1998-01-08
TR199700522A2 (xx) 1998-01-21
AU727851B2 (en) 2001-01-04
CN1173330A (zh) 1998-02-18
HUP9701068A3 (en) 2000-07-28
DE69710390D1 (de) 2002-03-21
NZ328113A (en) 1999-09-29
HUP9701068A2 (hu) 1998-08-28
AR007609A1 (es) 1999-11-10
CA2208199A1 (en) 1997-12-19
CZ290691B6 (cs) 2002-09-11
ID17051A (id) 1997-12-04
JP2009137970A (ja) 2009-06-25
MX9704579A (es) 1998-07-31
RU2181287C2 (ru) 2002-04-20
PT813873E (pt) 2002-06-28
US5977099A (en) 1999-11-02
SG60073A1 (en) 1999-02-22
JP4925074B2 (ja) 2012-04-25
ZA975335B (en) 1998-01-26
TR199700522A3 (tr) 1998-01-21
NO972816L (no) 1997-12-22
HU9701068D0 (en) 1997-08-28
JPH1067663A (ja) 1998-03-10
PL320628A1 (en) 1997-12-22
DE69710390T2 (de) 2002-08-14
ATE213159T1 (de) 2002-02-15
KR100481254B1 (ko) 2005-09-12
CZ187097A3 (cs) 1998-01-14
PL188520B1 (pl) 2005-02-28
NO313177B1 (no) 2002-08-26

Similar Documents

Publication Publication Date Title
KR980000447A (ko) 미르타자핀과 하나 이상의 선택적인 세로토닌 재이용 저해제로 이루어진 약학 조성물
RU97110083A (ru) Комбинация, фармацевтическая композиция, способ лечения, использование и упаковка
RU2009113038A (ru) Комбинированная лекарственная терапия для лечения ожирения
UY28041A1 (es) Metodos de dosis bajas para el tratamiento de trastornos en los cuales la actividad del tnfa es perjudicial.
CO5670327A2 (es) Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion
AR023715A1 (es) Composicion farmaceutica para un sujeto que necesita una elevacion del contenido de nad intracelular, y el uso de la misma para la manufactura de unmedicamento para aumentar las respuestas celulares protectoras al stress genotoxico en la piel
BR0112661A (pt) Nova combinação de agonista (5ht2) e antagonista (5ht6) da serotonina como formulação farmacêutica
BRPI0314308B8 (pt) antagonistas de opióide, seus usos, e composição farmacêutica
Nelson Augmentation strategies with serotonergic-noradrenergic combinations
KR920702220A (ko) 산화적 손상에 관련된 질병을 억제하기 위한 방법 및 그 조성물
ATE506059T1 (de) Therapie zur behandlung der überaktiven blase
AR035158A1 (es) Inhibidores de recaptacion de norepinefrina altamente selectivos y metodo para usar los mismos
NO2012015I2 (no) Dapoxetine
BR0012951A (pt) Agonistas de retinóides seletivos
AR013001A1 (es) Derivados de la piperazina, procedimientos para prepararlos, las composiciones farmaceuticas que los contienen, su utilizacion como medicamentoy el metodo para tratar enfermedades mediadas por la taquinina.
EP1254668A3 (en) Combination of a serotonin reuptake inhibitor and a GABA-A alpha 2/3 agonist for use in anxiety and depression
DE50114474D1 (de) Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen
BR0111982A (pt) Tratamento com apomorfina, de disfunção sexual induzida por droga anti depressão
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
BR0013582A (pt) Agonistas retinóides seletivos para rar
DK1091733T3 (da) (-)-Pseudoephedrin som et sympatomimetisk lægemiddel
BR0111002A (pt) Combinação de secretagogos do hormÈnio do crescimento e antidepressivos
JP2002530341A5 (ko)
WO1995000154B1 (en) Antidepressant agents with a rapid onset of action
CO4870761A1 (es) Composiciones farmaceuticas que comprenden hidroxicina y un inhibidor de la captacion de serotonina para el tratamiento de un transtorno depresivo

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20080326

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee